AcquisitionOther

Syros Pharmaceuticals, Inc. acquired TYME, including its pipeline assets

Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.

Deal tape row

Syros Pharmaceuticals, Inc. -> TYME, including its pipeline assets · $190 Million

Together, these decisions allow us to focus on the most advanced programs across our targeted hematology portfolio where we believe we can more rapidly address significant unmet needs.

Open source record (SEC) ↗